MediClin AG: Capital increase successfully completed

Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act)

Frankfurt am Main, December 9, 2008 – The capital increase, which was decided upon by the Management Board and approved by the Supervisory Board on November 21, 2008, has been successfully completed. Upon the successful registration of the recapitalization in the Corporate Register (Handelsregister), the registered share capital of the company has been raised from 31,500,000.00 EUR by 15,750,000.00 EUR to 47,250,000.00 EUR through the issuance of 15,750,000 new bearer shares without par value (Stückaktien) for cash with a share amount in the registered share capital of 1.00 EUR per share and with full dividend rights as of January 1, 2008. The inclusion of the new shares in the current listing of the Regulated Market on the Frankfurter Wertpapierboerse (Prime Standard) is planned for December 10, 2008.

Within the rights offering the new shares were subscribed for more than 99.9% at an exercise price of 2.50 EUR per new share. As a result, MEDICLIN Aktiengesellschaft has received a net amount of around 37.8 million EUR through the recapitalization, which will be used for the financing of acquisitions and for the planned repayment of existing company debt as well as debt which arises in connection with potential acquisitions.

Important Information

This publication constitutes neither an offer to sell nor a solicitation of an offer to buy any securities. The securities of MediClin Aktiengesellschaft offered in connection with the rights offering have already been sold. This publication and the information contained herein are not for distribution in or into the United States of America and must not be distributed to publications with a general circulation in the United States. The securities of MediClin Aktiengesellschaft have not been registered under the U. S. Securities Act of 1933, as amended, (“Securities Act”) and may not be offered, sold or delivered within the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of securities of in the United States. This publication is directed only at persons (I) who are outside the United Kingdom or (II) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (III) who fall within Article 49(2)(A) to (D) (“High Net Worth Companies, Unincorporated Associations etc.”) of the Order (all such persons being together referred to as “relevant persons”). Any person who is not a relevant person must not act or rely on this publication or any of its contents. Any investment or investment activity to which this publication relates is available only to relevant persons and will be engaged in only with relevant persons. 

About MediClin AG (Ticker: MED; WKN: 659 510)

MediClin AG is a nation-wide clinic operator and large provider of services in the area of Psycho- and Neurosciences as well as Orthopaedic. With 33 clinics and eight nursing care facilities and three Medizinische Versorgungszentren (medical care units) in eleven federal states MediClin has a total capacity of approximately 7,900 beds. MediClin’s facilities include acute care clinics, i.e., general hospitals, special treatment facilities, specialised hospitals and clinics for post-acute treatment and medical rehabilitation. MediClin has approximately 7,800 employees.